Aethlon Medical advances Australian oncology study to final cohort

Aethlon Medical reported fiscal year 2026 results and announced progression of its Australian oncology trial into Cohort 3, the final dosing phase, with the first participant treated. The company strengthened its Hemopurifier intellectual property portfolio with new patents extending protection into the 2040s while expanding preclinical research into rheumatoid arthritis and chronic kidney disease applications.